Since its founding in 2015, XtalPi (XtalPi Inc., 2228.HK) has consistently strengthened its frontier technological capabilities. Deeply rooted in original innovation within the biopharmaceutical industry, the company has expanded its high-value R&D applications to new materials, energy, chemicals, and agricultural technology, achieving significant milestones across multiple key sectors. Following its successful listing on the Hong Kong Stock Exchange in June 2024, XtalPi has been included in several major indices, including the MSCI China Index, Hang Seng Composite Index, Hang Seng Biotech Index, and HKEX Tech 100 Index, as well as the Shenzhen-Hong Kong and Shanghai-Hong Kong Stock Connect programs. These achievements signal XtalPi’s entry into a new phase of high-speed growth and the continuous realization of its long-term value.
Recently, XtalPi was honored with the 2025 [ESG Pioneer 60] Annual Corporate ESG Practice Award, alongside several other accolades from the capital markets and the biopharmaceutical industry. These awards recognize XtalPi’s technological prowess, commercial success, and long-term investment value, reflecting high praise from capital markets, leading financial media, and industry think tanks for the company’s leadership and development potential.
China Securities Journal: 2025 Golden Bull Award
At the 2025 Listed Companies (Hong Kong Stocks) Golden Bull Awards, XtalPi was awarded the “Golden Bull Science and Technology Innovation Award” for the first time. Other winners included industry leaders such as CATL, Sinopec, Hengrui Medicine, and Fuyao Glass. Established in 1999, the Golden Bull Award is one of China’s most credible capital market honors, focusing on companies that demonstrate excellence in institutional innovation and industrial transformation.
Shanghai Securities News: 2025 Golden Quality Award
At the 2025 Shanghai Securities (Chaohu) High-Quality Development Conference, XtalPi received the “Emerging Tech Innovation Enterprise Award.” Hosted by the Shanghai Securities News, this award serves as an authoritative benchmark for measuring the comprehensive strength and innovation-driven growth of listed companies in China.
Forbes China: 2025 High Investment Value Enterprise
Forbes China recently released its “2025 Forbes China Family Office Series Selection Awards,” where XtalPi was named a “2025 High Investment Value Enterprise.” This selection highlights innovation benchmarks across various fields and serves as a vital reference for global investors to identify market trends and opportunities.
Zhitong Caijing: 2025 Golden Hong Kong Stock Awards
At the 10th Zhitong Caijing Listed Company Awards, XtalPi won the “2025 Golden Hong Kong Stock Grand Prize” and the “Best IR Team Award.” Other recipients of the Grand Prize included Lenovo, BeiGene, and CITIC Limited. This award focuses on HK-listed companies with robust governance, high growth potential, and a commitment to social responsibility.
WIM2025: Top 10 Chinese Biopharmaceutical Innovation Enterprises
At the WIM2025 World Innovators Conference hosted by EqualOcean, XtalPi was named to the “2025 Top 10 Chinese Biopharmaceutical Innovation Enterprises” list. This selection is widely regarded as a professional barometer of a company’s technological breakthroughs and commercial influence within the “future industries” sector.
